BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

NEW YORK & PETACH TIKVAH, Israel-- --BrainStorm Cell Therapeutics , a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate.

http://www.businesswire.com/news/topix/20121217005532/en